Immatics (IMTX) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $7.14, +2.00% vs the prior close of $7.00.
- Volume 1.63M shares, 2.3x its 50-day average (heavy).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
IMTX rises 2.0% to $7.14 on 2.3x normal volume. Closed at $7.14, +2.00% vs the prior close of $7.00. Day range $6.95–$7.21, opened at $7.05.
IMTX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — IMTX rises 2.0% to $7.14 on 2.3x normal volume
- Closed at $7.14, +2.00% vs the prior close of $7.00. Day range $6.95–$7.21, opened at $7.05.
- Volume was 1.63M shares, 2.3x its 50-day average of 719.98K — unusually heavy trading.
- Price is -18.1% vs its 50-day average ($8.72) and -26.6% vs its 200-day average ($9.72).
- 52-week range $6.73–$12.41; today's close sits at 7% of that range, 42.5% below the 52-week high.
Oct 14, 2026 — IMTX rises 2.5% to $7.00 on 2.2x normal volume
- Closed at $7.00, +2.49% vs the prior close of $6.83. Day range $6.73–$7.20, opened at $7.00.
- Volume was 1.57M shares, 2.2x its 50-day average of 697.50K — unusually heavy trading.
- Price is -20.2% vs its 50-day average ($8.77) and -28.1% vs its 200-day average ($9.74).
- 52-week range $6.73–$12.41; today's close sits at 5% of that range, 43.6% below the 52-week high.
Oct 13, 2026 — IMTX slides 5.3% to $6.83, a 52-week low
- Closed at $6.83, -5.27% vs the prior close of $7.21. Day range $6.80–$7.28, opened at $7.17.
- Volume was 928.00K shares, 1.4x its 50-day average of 684.09K.
- Price is -22.5% vs its 50-day average ($8.82) and -30.0% vs its 200-day average ($9.76).
- 52-week range $6.80–$12.41; today's close sits at 1% of that range, 45.0% below the 52-week high.
Oct 12, 2026 — IMTX dips 3.0% to $7.21, a 52-week low
- Closed at $7.21, -2.96% vs the prior close of $7.43. Day range $7.14–$7.42, opened at $7.41.
- Volume was 750.40K shares, 1.1x its 50-day average of 673.34K.
- Price is -18.6% vs its 50-day average ($8.86) and -26.2% vs its 200-day average ($9.77).
- 52-week range $7.02–$12.41; today's close sits at 4% of that range, 41.9% below the 52-week high.
Oct 9, 2026 — IMTX rises 0.8% to $7.43 on 2.0x normal volume
- Closed at $7.43, +0.81% vs the prior close of $7.37. Day range $7.21–$7.45, opened at $7.37.
- Volume was 1.37M shares, 2.0x its 50-day average of 678.07K — unusually heavy trading.
- Price is -16.4% vs its 50-day average ($8.89) and -24.1% vs its 200-day average ($9.79).
- 52-week range $7.02–$12.41; today's close sits at 8% of that range, 40.1% below the 52-week high.
Oct 8, 2026 — IMTX dips 1.1% to $7.37, a 52-week low, 3 down days in a row
- Closed at $7.37, -1.07% vs the prior close of $7.45. Day range $7.02–$7.56, opened at $7.37.
- Volume was 604.70K shares, 0.9x its 50-day average of 674.66K.
- Price is -17.4% vs its 50-day average ($8.92) and -24.8% vs its 200-day average ($9.80).
- 52-week range $7.02–$12.41; today's close sits at 6% of that range, 40.6% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — IMTX dips 0.7% to $7.45, a 52-week low
- Closed at $7.45, -0.67% vs the prior close of $7.50. Day range $7.31–$7.70, opened at $7.44.
- Volume was 926.00K shares, 1.4x its 50-day average of 666.84K.
- Price is -16.8% vs its 50-day average ($8.96) and -24.1% vs its 200-day average ($9.82).
- 52-week range $7.31–$12.41; today's close sits at 3% of that range, 40.0% below the 52-week high.
Oct 6, 2026 — IMTX dips 3.0% to $7.50, a 52-week low
- Closed at $7.50, -2.98% vs the prior close of $7.73. Day range $7.47–$7.81, opened at $7.76.
- Volume was 974.40K shares, 1.5x its 50-day average of 656.41K.
- Price is -16.5% vs its 50-day average ($8.98) and -23.7% vs its 200-day average ($9.83).
- 52-week range $7.40–$12.41; today's close sits at 2% of that range, 39.6% below the 52-week high.
Oct 5, 2026 — IMTX rises 1.8% to $7.73
- Closed at $7.73, +1.84% vs the prior close of $7.59. Day range $7.47–$7.85, opened at $7.57.
- Volume was 554.10K shares, 0.9x its 50-day average of 651.14K.
- Price is -14.2% vs its 50-day average ($9.01) and -21.4% vs its 200-day average ($9.84).
- 52-week range $7.40–$12.41; today's close sits at 7% of that range, 37.7% below the 52-week high.
Oct 2, 2026 — IMTX slides 10.1% to $7.59, a 52-week low on 2.0x normal volume
- Closed at $7.59, -10.07% vs the prior close of $8.44. Day range $7.40–$8.57, opened at $8.56.
- Volume was 1.26M shares, 2.0x its 50-day average of 633.06K — unusually heavy trading.
- Price is -16.0% vs its 50-day average ($9.03) and -23.0% vs its 200-day average ($9.85).
- 52-week range $7.40–$12.41; today's close sits at 4% of that range, 38.8% below the 52-week high.
IMTX latest news & SEC filings
Every SEC filing by or about IMTX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Aug 27, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Edelman Joseph bought 863,060 shares at $8.69 (≈$7.50M) on Aug 26, 2026
- Perceptive Life Sciences Master Fund Ltd bought 863,060 shares at $8.69 (≈$7.50M) on Aug 26, 2026
- Perceptive Advisors Llc bought 863,060 shares at $8.69 (≈$7.50M) on Aug 26, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 27, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 26, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Aug 25, 2026 · Form 424B2 — Prospectus for a securities offering
Prospectus for a securities offering
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 18, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 29, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Jun 25, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Jun 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 18, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Things to know before you trade IMTX
- How much it moves: over the last 20 sessions the average daily move was 2.53% (largest 10.1%).
- Liquidity: about 995.62K shares (≈$7.11M) trade per day on average.
- 52-week position: $7.14 vs a range of $6.73–$12.41 (7% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 3 open-market buys, 0 sales; latest: Joseph Edelman bought 863,060 shares on Aug 26, 2026.
- Latest filings: 6-K Aug 26, 2026; 6-K Aug 18, 2026; 6-K Jun 18, 2026.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
IMTX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 7.05 | 7.21 | 6.95 | 7.14 | 1.63M |
| Oct 14, 2026 | 7.00 | 7.20 | 6.73 | 7.00 | 1.57M |
| Oct 13, 2026 | 7.17 | 7.28 | 6.80 | 6.83 | 928.00K |
| Oct 12, 2026 | 7.41 | 7.42 | 7.14 | 7.21 | 750.40K |
| Oct 9, 2026 | 7.37 | 7.45 | 7.21 | 7.43 | 1.37M |
| Oct 8, 2026 | 7.37 | 7.56 | 7.02 | 7.37 | 604.70K |
| Oct 7, 2026 | 7.44 | 7.70 | 7.31 | 7.45 | 926.00K |
| Oct 6, 2026 | 7.76 | 7.81 | 7.47 | 7.50 | 974.40K |
| Oct 5, 2026 | 7.57 | 7.85 | 7.47 | 7.73 | 554.10K |
| Oct 2, 2026 | 8.56 | 8.57 | 7.40 | 7.59 | 1.26M |
| Oct 1, 2026 | 8.72 | 8.85 | 8.43 | 8.44 | 639.70K |
| Sep 30, 2026 | 8.56 | 9.16 | 8.43 | 8.78 | 1.90M |
| Sep 29, 2026 | 8.50 | 8.69 | 8.39 | 8.56 | 644.30K |
| Sep 28, 2026 | 8.35 | 8.59 | 8.20 | 8.50 | 1.47M |
| Sep 25, 2026 | 8.39 | 8.50 | 8.25 | 8.37 | 378.80K |
| Sep 24, 2026 | 8.52 | 8.57 | 8.06 | 8.33 | 2.37M |
| Sep 23, 2026 | 8.80 | 8.89 | 8.57 | 8.60 | 384.20K |
| Sep 22, 2026 | 8.77 | 8.89 | 8.71 | 8.87 | 501.60K |
| Sep 21, 2026 | 8.76 | 8.87 | 8.58 | 8.72 | 305.30K |
| Sep 18, 2026 | 8.76 | 8.85 | 8.48 | 8.62 | 759.90K |
About Immatics
Immatics (IMTX) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in TUBINGEN, Germany. State of incorporation: Netherlands. Fiscal year ends December 31. SEC CIK 1809196.
IMTX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Michael G Atieh | Director | Jun 18, 2026 |
| Paul Rutherford Carter | Director | Jun 18, 2026 |
| Peter Alan Chambre | Director | Jun 18, 2026 |
| Joseph Edelman | Director | Aug 27, 2026 |
| Eliot Forster | Director | Jun 18, 2026 |
| Mathias Hothum | Director | Jun 18, 2026 |
| Heather L Mason | Director | Jun 18, 2026 |
| Advisors Llc Perceptive | Director | Aug 27, 2026 |
| Life Sciences Master Fund Ltd Perceptive | Director | Aug 27, 2026 |
| Alise Reicin | Director | Jun 18, 2026 |
| Jasuja Harpreet Singh | Chief Executive Officer | Mar 18, 2026 |
| Adam Leo Stone | Director | Jun 18, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Cedrik Michael Britten | Chief Medical Officer | Mar 18, 2026 |
| Rainer Kramer | Chief Business Officer | Mar 18, 2026 |
| Amie Elizabeth Krause | Chief People Officer | Mar 18, 2026 |
| James Nelson Pepin | Gen Counsel and Corp Secretary | Aug 18, 2026 |
| Venkat Ramanan | Chief Financial Officer | Mar 18, 2026 |
| Carsten Alexander Johannes Reinhardt | Chief Development Officer | Mar 18, 2026 |
| Jordan Zeik Silverstein | Head of Strategy | Mar 18, 2026 |
| Jasuja Harpreet Singh | Chief Executive Officer | Mar 18, 2026 |
| Edward A Jr Sturchio | General Counsel | Mar 18, 2026 |
| Steffen Martin Walter | Chief Operating Officer | Mar 18, 2026 |
| Toni Michael Weinschenk | Chief Innovation Officer | Mar 18, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 26, 2026 | Joseph Edelman | Buy | 863,060 | $8.69 |
| Aug 26, 2026 | Life Sciences Master Fund Ltd Perceptive | Buy | 863,060 | $8.69 |
| Aug 26, 2026 | Advisors Llc Perceptive | Buy | 863,060 | $8.69 |
IMTX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| No annual XBRL figures available (foreign filers often report on Form 20-F). | ||||
Latest balance sheet: total assets $—, total liabilities $—, cash $—.
IMTX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| No 8-K earnings releases in recent filings. | ||
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Argenx Se (ARGX)Biogen (BIIB)Halozyme Therapeutics (HALO)Revolution Medicines (RVMD)Recursion Pharmaceuticals (RXRX)ImmunityBio (IBRX)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on IMTX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.